Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views
Ratings for Protagonist Therapeutics (NASDAQ:PTGX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $102.38, a high estimate of $117.00, and a low estimate of $81.00. This current average has increased by 24.28% from the previous average price target of $82.38.
Decoding Analyst Ratings: A Detailed Look
The standing of Protagonist Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $117.00 | $80.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $110.00 | $88.00 |
| Etzer Darout | Barclays | Raises | Overweight | $108.00 | $88.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $115.00 | $98.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $98.00 | $96.00 |
| Brian Cheng | JP Morgan | Raises | Overweight | $81.00 | $68.00 |
| Etzer Darout | Barclays | Raises | Overweight | $88.00 | $72.00 |
| Jonathan Wolleben | Citizens | Raises | Market Outperform | $102.00 | $69.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Protagonist Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Protagonist Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Protagonist Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
For valuable insights into Protagonist Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Protagonist Therapeutics analyst ratings.
Get to Know Protagonist Therapeutics Better
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Protagonist Therapeutics's Economic Impact: An Analysis
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Protagonist Therapeutics showcased positive performance, achieving a revenue growth rate of 0.79% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -834.87%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Protagonist Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.99%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Protagonist Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.54%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Protagonist Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.